MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.98
+0.07
+0.89%
After Hours: 7.98 0 0.00% 19:47 02/26 EST
OPEN
7.98
PREV CLOSE
7.91
HIGH
8.13
LOW
7.56
VOLUME
716.75K
TURNOVER
--
52 WEEK HIGH
30.10
52 WEEK LOW
1.436
MARKET CAP
182.22M
P/E (TTM)
-3.5393
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
HTBX: HS-110 Phase 2 Interim Data
By John Vandermosten, CFA NASDAQ:HTBX READ THE PREVIOUS HTBX RESEARCH REPORT HS-110 Interim Data Heat Biologics, Inc. (NASDAQ:HTBX) announced positive interim survival data for its Phase II trial of HS-110 (viagenpumatucel-L), a cell-based therapy, in comb...
Zacks Small Cap Research · 02/16 13:08
Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference
DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product .
ACCESSWIRE · 02/12 20:00
Is Heat Biologics Stock a Buy Right Now? Analyst Weighs In
Tuesday was a good day for investors of Heat Biologics (HTBX). Shares blasted off by 50%, after the biotech company announced positive interim data for its lung cancer treatment. Specifically, in the Phase 2 trial of HS-110, in combination with Bristol-Mye...
TipRanks · 02/10 19:44
Heat Biologics Stock Notches Scorching RS Rating
Investor's Business Daily · 02/10 18:40
Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027
, /PRNewswire/ -- The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the sid...
PR Newswire - PRF · 02/10 13:45
Mid-Afternoon Market Update: Dow Rises 50 Points; Heat Biologics Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.16% to 31,436 while the NASDAQ rose 0.28% to 14,026.29. The S&P also rose, gaining 0.04% to 3,917.21.
Benzinga · 02/09 19:47
DJ Heat Biologics Shares Rise 55% After Positive Data for Lung Cancer Treatment
Dow Jones · 02/09 18:29
DJ Heat Biologics Up Over 63%, On Pace for Largest Percent Increase Since March 2020 -- Data Talk
Dow Jones · 02/09 17:56
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTBX. Analyze the recent business situations of Heat Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTBX stock price target is 29.25 with a high estimate of 40.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 2.33M
% Owned: 10.19%
Shares Outstanding: 22.84M
TypeInstitutionsShares
Increased
10
273.01K
New
22
442.81K
Decreased
10
12.91K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Wolf
Chief Financial Officer
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About HTBX
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTBX stock methods without spending real money on the virtual paper trading platform.